Login to Your Account

DOV Shares Crushed After Phase III Bicifadine Failure

By Aaron Lorenzo

Wednesday, April 26, 2006
Poor Phase III data nearly halved DOV Pharmaceutical Inc.'s stock value Tuesday after the findings were unveiled late Monday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription